新生儿卡介苗接种与 13 个月前的特应性皮炎：一项随机临床试验。

Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial.

机构信息

Paediatric Department, Kolding Hospital, Kolding, Denmark.

Paediatric Department, Rigshospitalet, Copenhagen, Denmark.

出版信息

Allergy. 2018 Feb;73(2):498-504. doi: 10.1111/all.13314. Epub 2017 Oct 9.

DOI:10.1111/all.13314

PMID:28929567

Abstract

BACKGROUND

Studies have suggested that Bacillus Calmette-Guérin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis.

METHODS

The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months.

RESULTS

Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control group (RR = 0.90 [95% confidence intervals 0.80-1.00]). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74-0.95)) and children without atopic predisposition (RR 1.09 [0.88-1.37]) (test of no interaction, P = .04).

CONCLUSION

Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12-76).

摘要

背景

研究表明，卡介苗（BCG）接种可能降低过敏性疾病（包括特应性皮炎）的风险。

方法

丹麦卡介苗研究于 2012-2015 年进行。新生儿在出生后 7 天内按 1:1 随机分为 BCG 组或非 BCG 组。排除标准为胎龄<32 周、出生体重<1000g、已知免疫缺陷或无丹麦语家长。数据通过电话访谈和临床检查收集，直至 13 个月。

结果

BCG 组 2052 名儿童中有 466 名（22.7%）和对照组 1952 名儿童中有 495 名（25.4%）被诊断为临床特应性皮炎（RR=0.90[95%置信区间 0.80-1.00]）。新生儿 BCG 接种对特应性倾向儿童（RR=0.84[0.74-0.95]）和无特应性倾向儿童（RR=1.09[0.88-1.37]）的影响差异有统计学意义（交互检验，P=0.04）。